Literature DB >> 23768260

Implementing panic-focused psychodynamic psychotherapy into clinical practice.

Manfred E Beutel1, Vera Scheurich, Achim Knebel, Matthias Michal, Jörg Wiltink, Mechthild Graf-Morgenstern, Regine Tschan, Barbara Milrod, Stefan Wellek, Claudia Subic-Wrana.   

Abstract

OBJECTIVE: To determine the effectiveness of manualized panic-focused psychodynamic psychotherapy (PFPP) in routine care in Germany.
METHOD: German psychoanalysts were trained according to the PFPP manual. Fifty-four consecutive outpatients with panic disorder (with or without agoraphobia) were randomly assigned in a 2:1 ratio to PFPP or cognitive-behavioural therapy (CBT) plus exposure therapy. Subjects (female 57.4%; mean age 36.2 years) had high rates of psychiatric (68.5%) and somatic (64.8%) comorbidity, and previous psychiatric treatments (57.4%). Assessments were performed pre- and posttreatment and at 6-month follow-up. The primary outcome measure was the Panic Disorder Severity Scale.
RESULTS: Both treatments were highly effective. In patients randomized to PFPP, remission was achieved in 44.4% at termination and by 50% at follow-up (CBT 61.1% and 55.6%, respectively). No significant differences were found. Emotional awareness, a posited moderator of good outcome in psychotherapies, was significantly higher in the CBT group at baseline. It was found to be a strong moderator of treatment effectiveness in both treatments. After adjusting for initial Levels of Emotional Awareness Scale (LEAS) scores, effect sizes (ESs) for the primary outcome were Cohen d = 1.28, from pre- to posttreatment, and d = 1.03, from pretreatment to follow-up, for PFPP, and d = 1.81 and 1.28 for CBT, respectively.
CONCLUSIONS: PFPP was implemented effectively into clinical practice by psychoanalysts in the community in a sample with severe mental illness with large ESs. Assessment of LEAS may facilitate the identification of patients suitable for short-term psychotherapy. ( CLINICAL TRIAL REGISTRATION NUMBER: German Clinical Trials Register, DRKS00000245; Universal Trial Number, U1111-1112-4245).

Entities:  

Keywords:  agoraphobia; cognitive-behavioural therapy; effectiveness; follow-up; panic disorder; panic-focused psychodynamic psychotherapy

Mesh:

Year:  2013        PMID: 23768260      PMCID: PMC8327327          DOI: 10.1177/070674371305800604

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  10 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  The Levels of Emotional Awareness Scale: a cognitive-developmental measure of emotion.

Authors:  R D Lane; D M Quinlan; G E Schwartz; P A Walker; S B Zeitlin
Journal:  J Pers Assess       Date:  1990

Review 3.  Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Authors:  T A Furukawa; N Watanabe; R Churchill
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis.

Authors:  Julio Sánchez-Meca; Ana I Rosa-Alcázar; Fulgencio Marín-Martínez; Antonia Gómez-Conesa
Journal:  Clin Psychol Rev       Date:  2010-02

5.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.

Authors:  D H Barlow; J M Gorman; M K Shear; S W Woods
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

6.  Multicenter collaborative panic disorder severity scale.

Authors:  M K Shear; T A Brown; D H Barlow; R Money; D E Sholomskas; S W Woods; J M Gorman; L A Papp
Journal:  Am J Psychiatry       Date:  1997-11       Impact factor: 18.112

7.  A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder.

Authors:  Barbara Milrod; Andrew C Leon; Fredric Busch; Marie Rudden; Michael Schwalberg; John Clarkin; Andrew Aronson; Meriamne Singer; Wendy Turchin; E Toby Klass; Elizabeth Graf; Jed J Teres; M Katherine Shear
Journal:  Am J Psychiatry       Date:  2007-02       Impact factor: 18.112

8.  Emotional awareness deficits in inpatients of a psychosomatic ward: a comparison of two different measures of alexithymia.

Authors:  Claudia Subic-Wrana; Susanne Bruder; Walther Thomas; Richard D Lane; Karl Köhle
Journal:  Psychosom Med       Date:  2005 May-Jun       Impact factor: 4.312

9.  Do comorbid personality disorders moderate panic-focused psychotherapy? An exploratory examination of the American Psychiatric Association practice guideline.

Authors:  Barbara L Milrod; Andrew C Leon; Jacques P Barber; John C Markowitz; Elizabeth Graf
Journal:  J Clin Psychiatry       Date:  2007-06       Impact factor: 4.384

10.  Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale.

Authors:  Toshi A Furukawa; M Katherine Shear; David H Barlow; Jack M Gorman; Scott W Woods; Roy Money; Eva Etschel; Rolf R Engel; Stefan Leucht
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

  10 in total
  11 in total

1.  The effectiveness of psychodynamic psychotherapies: An update.

Authors:  Peter Fonagy
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Prediction and moderation of improvement in cognitive-behavioral and psychodynamic psychotherapy for panic disorder.

Authors:  Dianne L Chambless; Barbara Milrod; Eliora Porter; Robert Gallop; Kevin S McCarthy; Elizabeth Graf; Marie Rudden; Brian A Sharpless; Jacques P Barber
Journal:  J Consult Clin Psychol       Date:  2017-06-26

3.  In-session emotional expression predicts symptomatic and panic-specific reflective functioning improvements in panic-focused psychodynamic psychotherapy.

Authors:  John R Keefe; Zeeshan M Huque; Robert J DeRubeis; Jacques P Barber; Barbara L Milrod; Dianne L Chambless
Journal:  Psychotherapy (Chic)       Date:  2019-03-14

4.  The POSE study - panic control treatment versus panic-focused psychodynamic psychotherapy under randomized and self-selection conditions: study protocol for a randomized controlled trial.

Authors:  Rolf Sandell; Martin Svensson; Thomas Nilsson; Håkan Johansson; Gardar Viborg; Sean Perrin
Journal:  Trials       Date:  2015-03-31       Impact factor: 2.279

5.  Transfer of manualized Short Term Psychodynamic Psychotherapy (STPP) for social anxiety disorder into clinical practice: results from a cluster-randomised controlled trial.

Authors:  Jörg Wiltink; Christian Ruckes; Jürgen Hoyer; Falk Leichsenring; Peter Joraschky; Frank Leweke; Karin Pöhlmann; Manfred E Beutel
Journal:  BMC Psychiatry       Date:  2017-03-14       Impact factor: 3.630

Review 6.  Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.

Authors:  Alessandro Pompoli; Toshi A Furukawa; Hissei Imai; Aran Tajika; Orestis Efthimiou; Georgia Salanti
Journal:  Cochrane Database Syst Rev       Date:  2016-04-13

7.  The role of medial prefrontal cortex in the working memory maintenance of one's own emotional responses.

Authors:  Ryan Smith; Richard D Lane; Anna Alkozei; Jennifer Bao; Courtney Smith; Anna Sanova; Matthew Nettles; William D S Killgore
Journal:  Sci Rep       Date:  2018-02-22       Impact factor: 4.379

8.  The Relationship Between Alexithymia and Emotional Awareness: A Meta-Analytic Review of the Correlation Between TAS-20 and LEAS.

Authors:  Daniel Maroti; Peter Lilliengren; Indre Bileviciute-Ljungar
Journal:  Front Psychol       Date:  2018-04-16

9.  Higher levels of trait emotional awareness are associated with more efficient global information integration throughout the brain: a graph-theoretic analysis of resting state functional connectivity.

Authors:  Ryan Smith; Anna Sanova; Anna Alkozei; Richard D Lane; William D S Killgore
Journal:  Soc Cogn Affect Neurosci       Date:  2018-09-04       Impact factor: 3.436

10.  The Bergen 4-Day Treatment for Panic Disorder: A Pilot Study.

Authors:  Bjarne Hansen; Gerd Kvale; Kristen Hagen; Kay M Hjelle; Stian Solem; Beate Bø; Lars-Göran Öst
Journal:  Front Psychol       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.